ULTOMIRIS® Rapid action that can deliver long–lasting control for your adult patients with generalised myasthenia gravis (gMG) who are anti–acetylcholine receptor (AChR) antibody–positive.*1–3

ULTOMIRIS® is the first-and-only long–acting complement inhibitor for AChR antibody–positive gMG patients that provides immediate, complete and sustained C5 inhibition; resulting in rapid and long-lasting symptom control by reducing neuromuscular junction (NMJ) functional impairment and preserving the integrity of neuromuscular transmission.1,2

ULTOMIRIS® is contraindicated in patients who are not currently vaccinated against Neisseria Meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination1 (further information is available under ‘dosing and administration’).

Please consult the Summary of Product Characteristics prior to prescribing.

* Based on MD-ADL, a categorical scale that accesses the impact on daily function of 8 signs and symptoms that are typically affected in gMG.4

† Once every 8 weeks, dosing starting 2 weeks after loading dose.1

‡ The efficacy and safety of ULTOMIRIS® in adult patients with anti-ACHR antibody-positive gMG was assessed in CHAMPION-MG, a Phase 3, randomised, placebo-controlled, multicentre study. Patients were randomly assigned (1:1) ULTOMIRIS® or placebo for 26 weeks. A total of 175 patients were enrolled.2

§ Adverse reactions from clinical trials and post-marketing experience. Please refer to the ULTOMIRIS® Summary of Product Characteristics for further adverse events and safety information.1
gMG is a rare autoimmune condition involving defective transmission at the neuromuscular junction (NMJ). Activation of the complement system plays a critical role in the pathophysiology of gMG.3
Disease progression is characterised by continuous deterioration at the NMJ affecting one or more muscle groups. Therefore, early, effective treatment is critical to preserve NMJ integrity and function3,8

Up to 20% of gMG patients do not achieve adequate
symptom control or are intolerant to
conventional treatment.9


AChR, acetylcholine receptor; C5, complement component 5; gMG, generalised myasthenia gravis; MG–ADL, Myasthenia Gravis–Activities of Daily Living; NMJ, neuromuscular junction.

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
ULTOMIRIS® (ravulizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: September 2024. Vu T, et al. Terminal complement inhibitor ravulizumab in generalised myasthenia gravis. N Eng J Med Evid. 2022;1(5). Meisel A, et al. Long-term efficacy and safety of ravulizumab in adults with acetyl-choline receptor antibody-positive generalised myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. [published online ahead of print]. J Neurol. 2023;1-14. Muppidi S, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011 ;44(5):727-731. Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann NY Acad Sci. 2018;1412(1):113-128. Conti-Fine BM, et al. Myasthenia gravis: past present and future. J Clin Invest. 2006;116(11):2843-2854. Vu T, et al. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalised myasthenia gravis. J Neurol. 2023;270(6):3129-37. Meriggioli MN et al. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8:475–90. Schneider–Gold C, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neural Disord. 2019;12:1–16. Braz NFT, et al. Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia-gravis. J Clin Neurosci. 2018;50:41–44 advance I am a healthcare professional registered in the EU I am not a
healthcare professional